GlassScriptPhysician profile
Nathan Tonlaar
NPI 1811284375
$2,409.56
in general payments reported to CMS, 2019-2025
10 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $69.53 · 2021: $34.49 · 2022: $773 · 2023: $566 · 2024: $414 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $851.58 | 2019-2025 | Optune, Optune Lua (Novottf-200t) |
| Siemens Medical Solutions USA, INC. | $444.32 | 2023-2025 | Edge, Aria Radiation Therapy Management Software, Truebeam |
| Boston Scientific Corporation | $425.59 | 2019-2022 | |
| Accuray Incorporated | $176.07 | 2019-2023 | Tomo Therapy System, Cyberknife System |
| Roche Diagnostics Corporation | $120.16 | 2022 | |
| Gt Medical Technologies, INC | $114.79 | 2022 | |
| Tempus Ai, INC | $113.89 | 2024 | |
| Medtronic, INC. | $104.85 | 2024 | Osteocool Rf Ablation System |
| Astrazeneca Pharmaceuticals LP | $42.79 | 2023-2025 | Imfinzi |
| Janssen Biotech, INC. | $15.52 | 2024 | Tecvayli, Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Tonlaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.